Vertex Pharmaceuticals Incorporated VRTX Stock
Vertex Pharmaceuticals Incorporated Price Chart
Vertex Pharmaceuticals Incorporated VRTX Financial and Trading Overview
| Vertex Pharmaceuticals Incorporated stock price | 468.42 USD |
| Previous Close | 451.63 USD |
| Open | 455.65 USD |
| Bid | 464.37 USD x 100 |
| Ask | 463.73 USD x 100 |
| Day's Range | 453.21 - 467.94 USD |
| 52 Week Range | 362.5 - 507.92 USD |
| Volume | 1.82M USD |
| Avg. Volume | 1.27M USD |
| Market Cap | 118.47B USD |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | 27.702671 |
| EPS (TTM) | 16.85 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 548.69 USD |
VRTX Valuation Measures
| Enterprise Value | 109.37B USD |
| Trailing P/E | 27.702671 |
| Forward P/E | 21.740112 |
| PEG Ratio (5 yr expected) | 1.7 |
| Price/Sales (ttm) | 9.696663 |
| Price/Book (mrq) | 6.1275415 |
| Enterprise Value/Revenue | 8.951 |
| Enterprise Value/EBITDA | 21.956 |
Trading Information
Vertex Pharmaceuticals Incorporated Stock Price History
| Beta (5Y Monthly) | 0.31 |
| 52-Week Change | 1.82% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 507.92 USD |
| 52 Week Low | 362.5 USD |
| 50-Day Moving Average | 438.06 USD |
| 200-Day Moving Average | 439.63 USD |
VRTX Share Statistics
| Avg. Volume (3 month) | 1.27M USD |
| Avg. Daily Volume (10-Days) | 1.43M USD |
| Shares Outstanding | 253.81M |
| Float | 253.02M |
| Short Ratio | 3.46 |
| % Held by Insiders | 0.20% |
| % Held by Institutions | 98.00% |
| Shares Short | 4.49M |
| Short % of Float | 2.00% |
| Short % of Shares Outstanding | 1.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 35.50% |
| Operating Margin (ttm) | 38.12% |
| Gross Margin | 54.39% |
| EBITDA Margin | 40.76% |
Management Effectiveness
| Return on Assets (ttm) | 12.14% |
| Return on Equity (ttm) | 24.19% |
Income Statement
| Revenue (ttm) | 12.22B USD |
| Revenue Per Share (ttm) | 47.91 USD |
| Quarterly Revenue Growth (yoy) | 7.79% |
| Gross Profit (ttm) | 6.65B USD |
| EBITDA | 4.98B USD |
| Net Income Avi to Common (ttm) | 4.34B USD |
| Diluted EPS (ttm) | 16.85 |
| Quarterly Earnings Growth (yoy) | 59.59% |
Balance Sheet
| Total Cash (mrq) | 7.25B USD |
| Total Cash Per Share (mrq) | 28.55 USD |
| Total Debt (mrq) | 1.99B USD |
| Total Debt/Equity (mrq) | 10.26 USD |
| Current Ratio (mrq) | 3.023 |
| Book Value Per Share (mrq) | 76.179 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 4.24B USD |
| Levered Free Cash Flow (ttm) | 2.78B USD |
Profile of Vertex Pharmaceuticals Incorporated
| Country | United States |
| State | MA |
| City | Boston |
| Address | 50 Northern Avenue |
| ZIP | 02210 |
| Phone | 617 341 6100 |
| Website | https://www.vrtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6400 |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Q&A For Vertex Pharmaceuticals Incorporated Stock
What is a current VRTX stock price?
Vertex Pharmaceuticals Incorporated VRTX stock price today per share is 468.42 USD.
How to purchase Vertex Pharmaceuticals Incorporated stock?
You can buy VRTX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vertex Pharmaceuticals Incorporated?
The stock symbol or ticker of Vertex Pharmaceuticals Incorporated is VRTX.
Which industry does the Vertex Pharmaceuticals Incorporated company belong to?
The Vertex Pharmaceuticals Incorporated industry is Biotechnology.
How many shares does Vertex Pharmaceuticals Incorporated have in circulation?
The max supply of Vertex Pharmaceuticals Incorporated shares is 253.81M.
What is Vertex Pharmaceuticals Incorporated Price to Earnings Ratio (PE Ratio)?
Vertex Pharmaceuticals Incorporated PE Ratio is 27.79940600 now.
What was Vertex Pharmaceuticals Incorporated earnings per share over the trailing 12 months (TTM)?
Vertex Pharmaceuticals Incorporated EPS is 16.85 USD over the trailing 12 months.
Which sector does the Vertex Pharmaceuticals Incorporated company belong to?
The Vertex Pharmaceuticals Incorporated sector is Healthcare.
Vertex Pharmaceuticals Incorporated VRTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
S&P 500 INDEX
SPX
US
|
7365.46 USD — |
-1.44
|
3.66B USD — | 7347.6 USD — | 7424.17 USD — | — - | 3.66B USD — |
|
S&P 500 (Yahoo.com)
GSPC
US
|
7365.46 USD — |
-1.44
|
3.66B USD — | 7347.6 USD — | 7424.17 USD — | — - | 3.66B USD — |
|
US100
NDX
US
|
29347.27 USD — |
-3.29
|
1.5B USD — | 29276.98 USD — | 29748.72 USD — | — - | 1.5B USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3033.18 USD — |
+1.08
|
100.05M USD — | 3015.75 USD — | 3040.05 USD — | — - | 100.05M USD — |
|
US Tech-100 ESG JPY Index
NDXESG07
US
|
3206.2 JPY 21.64 USD |
-3.21
|
— — | 3197.77 JPY 21.59 USD | 3247.62 JPY 21.92 USD | — - | — — |
|
US Tech-100 Total Return
XNDX
US
|
35811.68 USD — |
-3.29
|
— — | 35725.91 USD — | 36301.56 USD — | — - | — — |
|
Stlmt ID US Tech 100
XQO
US
|
16266.86 USD — |
-0.45
|
— — | 15738.2 USD — | 16639.8 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
6750.7 USD — |
+0.85
|
— — | 6680.28 USD — | 6803.27 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
US Tech-100 After Hours Indicato
QIV
US
|
29489.49 USD — |
-2.83
|
— — | 29365.41 USD — | 29492.37 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
1926.14 USD — |
+1.34
|
— — | 1902.55 USD — | 1929.69 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech DM Ex Japan Large Mid Ca
NQDMXJPLMAUD
US
|
2100.38 AUD 1467.26 USD |
<0.01
|
— — | 2100.38 AUD 1467.26 USD | 2100.38 AUD 1467.26 USD | — - | — — |
|
US Tech-100 ESG Net Notional Tot
NDXESG24
US
|
2340.14 EUR 2701.3 USD |
-2.82
|
— — | 2332.97 EUR 2693.03 USD | 2370.21 EUR 2736.02 USD | — - | — — |
|
US Tech-100 Notional Net Total R
XNDXNNR
US
|
34179.22 USD — |
-3.29
|
— — | 34097.35 USD — | 34646.76 USD — | — - | — — |
|
US Tech-100 Equal Weighted
NDXE
US
|
10041.73 USD — |
-2.15
|
— — | 10017.5 USD — | 10127.37 USD — | — - | — — |
|
US Tech-100 Micro Index
XND
US
|
293.47 USD — |
-3.29
|
— — | 292.77 USD — | 297.49 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}